Alprazolam ( DrugBank: Alprazolam )
2 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
8 | Huntington disease | 1 |
75 | Cushing disease | 1 |
8. Huntington disease
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00975481 (ClinicalTrials.gov) | October 2009 | 10/9/2009 | A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users | A Randomized, Double-Blind, Placebo- And Active-Controlled Single-Dose, Crossover Study To Evaluate The Abuse Potential Of Single Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users | Alzheimer's Disease;Huntington's Disease | Drug: dimebon;Drug: placebo;Drug: alprazolam | Pfizer | Medivation, Inc. | Completed | 18 Years | 55 Years | All | 36 | Phase 1 | Canada |
75. Cushing disease
Clinical trials : 205 / Drugs : 176 - (DrugBank : 45) / Drug target genes : 61 - Drug target pathways : 127
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-jRCT1021210011 | 13/04/2022 | 13/04/2022 | A diagnosis of pseudo-Cushing's syndrome using dexamethason/CRH and Alprazolam | A diagnosis of pseudo-Cushing's syndrome using dexamethason/CRH and anxiolytic Alprazolam | Pseudo Cushing's Syndrome Glucocorticoid , Stress, dexamethasone suppression test;D003480 | In patients suspected of having Cushing's syndrome or pseudo-Cushing's syndrome, we perform two loading tests, DEX/CRH and alprazolam tests, in order to confirm the differential ability of these tests. | Asari Yuko | NULL | Recruiting | Not applicable | Not applicable | Both | 20 | Phase 2 | Japan |